Zyclara (imiquimod)

P4, N=60, Not yet recruiting, China-Japan Friendship Hospital; China-Japan Friendship Hospital

P2, N=45, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university

P1, N=117, Active, not recruiting, M.D. Anderson Cancer Center | Enrolling by invitation --> Active, not recruiting

Both imiquimod and gardiquimod treatment inhibited tumor growth, with gardiquimod showing an increased potency compared to imiquimod. This implies that TLR agonists like imiquimod and gardiquimod could serve as neoadjuvant, adjuvant, or complementary immunotherapeutic agents in melanoma therapy.

P3, N=1630, Not yet recruiting, VA Office of Research and Development | Trial completion date: Jan 2032 --> May 2032 | Trial primary completion date: Jan 2032 --> May 2032

Immune modulation with PD-1/PD-L1 blockade, imiquimod, HPV vaccination, or OX40 stimulation enhanced effector function. The cSCC immune microenvironment reflects a balance between cytotoxic and suppressive factors. Harmonizing multimodal immune profiling and integrating spatial context with systemic immune status may advance both prognostic stratification and therapeutic design.

NCHBL-005 and its metabolite indole-3-acetaldehyde alleviate psoriatic inflammation through modulation of the aryl hydrocarbon receptor-interleukin-1 beta-interleukin-17A axis, thereby restoring skin immune homeostasis. This study highlights postbiotic intervention in the aryl hydrocarbon receptor-interleukin-1 beta-interleukin-17A axis as a promising therapeutic strategy for psoriasis.

Our findings identify IL-27 signaling in keratinocytes as a pivotal regulator of skin inflammation in both psoriasis and AD. This highlights IL-27 as a promising therapeutic target for inflammatory skin diseases.

Moreover, compound 2 showed a potent therapeutic effect on the psoriasiform skin lesions induced by imiquimod in mice by inhibiting the expression of S100A9 and keratinocyte proliferation. As the pioneering examples of natural products demonstrate inhibitory action against S100A8/A9 complex, this discovery provides a series of compelling lead compounds with novel molecular scaffold for treating psoriasis.

Despite appropriate topical treatment with imiquimod, adjunctive cryotherapy, and herbal immunomodulatory agents, the lesions remained resistant to therapy. Consideration of genital examination and prophylactic HPV vaccination prior to initiating JAK inhibitor therapy may be warranted. Furthermore, in cases of treatment-resistant genital warts, reassessing the patient's systemic immune status and current immunosuppressive medications may lead to improved clinical outcomes.

In this work, we report on absorbable microspheres with excellent loading and controlled release of epirubicin and imiquimod, a toll-like receptor 7 agonist (EPI/IMQ@Asphere) for transarterial chemo-immuno-embolization (TACIE) in liver tumors. TACIE in orthotopic VX2 rabbit model reveals significant shrinkage of primary liver tumor and complete prevention of pulmonary metastasis, in which TACIE not only occludes tumor arteries and kills tumor cells but also amplifies tumoral CD8+/CD4+ T cell infiltration. Overall, TACIE based on EPI/IMQ@Asphere offers a highly appealing therapeutic strategy for advanced liver cancers.

P2, N=16, Completed, Melanoma Institute Australia | Recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2025 | Trial primary completion date: Jun 2026 --> Mar 2025